Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Employees

364

Sector

Biotechnology & Medical Research

Calendar

08/09/2024 - H.C. Wainwright Global Investment Conference

Related indices

Russell 2000

More about the company

Quotes

Date	Price	Change	Volume
06/09/24	25.25 $	0.00%	695,238
05/09/24	25.25 $	+0.36%	708,799
04/09/24	25.16 $	+0.16%	702,017
03/09/24	25.12 $	+2.78%	1,439,573
30/08/24	24.44 $	+0.16%	763,634

Delayed Quote Nasdaq, September 06, 2024 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.25USD

Average target price

39.21USD

Spread / Average Target

+55.30%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 06/09/2024 BST			5-day change	1st Jan Change
25.25 ^USD	0.00%		+3.31%	+17.66%

09-05	Transcript : Denali Therapeutics Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 03:20 PM
09-04	Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating	MT

Capitalization	3.61B 275B	P/E ratio 2024 *	-9.94x	P/E ratio 2025 *	-9.57x
Enterprise value	2.36B 180B	EV / Sales 2024 *	122x	EV / Sales 2025 *	37.2x
Free-Float	86.37%	Yield 2024 *	-	Yield 2025 *	-

Transcript : Denali Therapeutics Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 03:20 PM	09-05
Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating	09-04	MT
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)	09-03	CI
Denali Therapeutics Insider Sold Shares Worth $549,928, According to a Recent SEC Filing	08-22	MT
B. Riley Adjusts Price Target on Denali Therapeutics to $33 From $36, Maintain Buy Rating	08-05	MT
Wedbush Adjusts Denali Therapeutics' PT to $26 From $30, Keeps Outperform Rating	08-02	MT
Denali Therapeutics Shares Fall After Swing to Q2 Net Loss	08-01	MT
Denali Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-01	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell Small Cap Comp Value Index	06-30	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000 Value Index	06-30	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2500 Value Index	06-30	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2000 Value Index	06-30	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000E Value Index	06-30	CI

Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating	09-04	MT
B. Riley Adjusts Price Target on Denali Therapeutics to $33 From $36, Maintain Buy Rating	08-05	MT
Wedbush Adjusts Denali Therapeutics' PT to $26 From $30, Keeps Outperform Rating	08-02	MT
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating	05-08	MT
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating	05-08	MT

Denali Therapeutics Inc. Share Price

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Valuation: Denali Therapeutics Inc.

Chart: Denali Therapeutics Inc.

Latest news: Denali Therapeutics Inc.

Last Transcript: Denali Therapeutics Inc.

Analysts' recommendations: Denali Therapeutics Inc.

Press Releases: Denali Therapeutics Inc.

News in other languages: Denali Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Denali Therapeutics Inc.

ETFs: Denali Therapeutics Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)	09-03	GL
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration	08-14	GL
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights	08-01	GL
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	06-13	AQ
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	06-03	GL

Sanofi : échec d'un essai de phase 2 contre la SLA	02-16
Pfizer y Flagship Pioneering invertirán 100 millones de dólares en el descubrimiento de fármacos	18/07/23
Biogen : remanie son programme contre la maladie de Parkison	05/06/23
En medio de la suspensión de la FDA, Denali pone en marcha un estudio sobre el Alzheimer en Europa -- Market Talk	05/07/22

1 week	+3.31%
Current month	+3.31%
1 month	+16.47%
3 months	+21.57%
6 months	+22.99%
Current year	+17.66%

Director	Title	Age	Since
Alexander Schuth FOU	Founder	50	13/10/13
Ryan Watts FOU	Founder	48	13/10/13
Joe Lewcock CTO	Chief Tech/Sci/R&D Officer	-	31/12/19

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.31%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.31%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
DENALI THERAPEUTICS INC.	0.00%	+3.31%	+4.43%	-53.22%	3.61B
REGENERON PHARMACEUTICALS, INC.	-1.66%	-4.49%	+37.11%	+69.18%	122B
VERTEX PHARMACEUTICALS INCORPORATED	-0.12%	-5.62%	+36.06%	+143.50%	121B
ARGENX SE	+0.27%	+4.17%	+1.75%	+67.91%	32.37B
BIONTECH SE	-0.23%	+1.95%	-24.88%	-74.05%	21.38B
BEIGENE, LTD.	-0.14%	-0.24%	-1.51%	-44.80%	20.33B
GENMAB A/S	-0.27%	-0.72%	-29.20%	-37.25%	17.58B
WUXI APPTEC CO., LTD.	-2.17%	-0.97%	-49.15%	-72.52%	15.54B
VAXCYTE, INC.	-0.46%	+38.16%	+123.97%	+330.81%	12.45B
SAREPTA THERAPEUTICS, INC.	-3.63%	-5.05%	+5.67%	+64.08%	12.29B
Average	-0.84%	+3.43%	+10.42%	+39.36%	37.85B
Weighted average by Cap.	-0.81%	-1.58%	+23.08%	+75.09%

	2024 *	2025 *
Net sales	19.31M 1.47B	68.78M 5.24B
Net income	-416M -31.71B	-454M -34.55B
Net Debt	-1.25B -95.52B	-1.06B -80.58B